LL-37 and Lyme disease: separating peptide hype from real data

What did @justagrownwoman actually say?

The creator described LL-37 as a naturally occurring immune peptide that acts like a "superhero and a smart detective" hunting down bad bacteria and viruses. She claimed it has made "amazing strides in the Lyme disease community," that it trains the immune system without causing overactivation, and that it requires medical guidance because taking it incorrectly can trigger flare-ups. That is a fairly packed set of claims for a 45-second video.

To her credit, she did not claim it cures anything. She flagged potency concerns and explicitly said it should be taken under medical supervision. For TikTok peptide content, that is a lower bar than usual, but she clears it. The Lyme disease angle is where things get murky, and that deserves a closer look.

Does the science back this up?

Partially, yes, but the research is nowhere near the level of confidence her framing implies. LL-37 is a real, well-studied antimicrobial peptide (AMP), part of the cathelicidin family, and your body does produce it naturally. The basic immunology she describes is grounded in legitimate science.

Lab studies confirm LL-37 disrupts bacterial membranes and has antiviral properties. Mookherjee and Hancock (2007, Expert Opinion on Biological Therapy) documented its dual role in direct microbial killing and immune modulation. The claim that it helps train the immune system without causing overactivation reflects real research into its immunomodulatory properties, including evidence that it can dampen excessive inflammatory signaling. Wang et al. (2014, Pharmaceuticals) found LL-37 influences neutrophil activity and cytokine responses in ways that could theoretically prevent overreaction.

The Lyme disease claim is a different story. There is preclinical interest, but no published clinical trials establishing LL-37 as an effective treatment for Lyme disease in humans. That gap matters enormously.

What did they get wrong (or right)?

She got the basic biology right. LL-37 is a naturally produced antimicrobial peptide. It does have documented activity against bacteria and some viruses in controlled settings. The immunomodulatory angle is also supported by peer-reviewed literature. Giving her credit where it is due: she did not claim this was a cure, and she flagged medical oversight. Those are responsible disclosures.

Where she overshoots is the Lyme disease framing. Saying LL-37 has made "amazing strides in the Lyme disease community" implies clinical progress that does not exist in the published literature. Community buzz is not the same as clinical evidence. Borrellia burgdorferi, the bacterium behind Lyme disease, is notoriously evasive, and the idea that any peptide simply "searches and destroys" it is a significant oversimplification.

The phrase "it finds these bad bacteria, bad viruses, searches and destroys" is evocative but imprecise. LL-37 does not distinguish pathogens with anything resembling targeted intelligence. It disrupts membranes, which is a blunt mechanism, not a smart one. That distinction matters clinically.

What should you actually know?

LL-37 is a legitimate subject of ongoing research, but the gap between lab findings and clinical use is wide. Most studies demonstrating its antimicrobial effects are in vitro or animal models. Human clinical trials are limited and generally focused on wound healing and skin conditions, not systemic infections like Lyme disease.

If you have Lyme disease or suspect you do, LL-37 peptide therapy is not an established treatment option. The standard of care remains antibiotics, typically doxycycline, as supported by Infectious Diseases Society of America guidelines. Using unregulated peptide compounds outside that framework carries real risks, including the "flare-ups" she mentioned, which in the Lyme context could reflect immune dysregulation rather than therapeutic benefit.

Compounded LL-37 peptides are not FDA-approved drugs. Quality, purity, and dosing consistency vary significantly between compounding pharmacies. If a clinician recommends this peptide for any indication, they should be able to point you to specific evidence, not community testimonials.